| ALP | acute leukemia protocol; acute lupus pericarditis; alkaline phosphatase; alveolar proteinosis; anter... |
|---|---|
| BILAG | British Isles Lupus Assessment Group [Index] |
| CDLE | chronic discoid lupus erythematosus |
| DIL, Dil | Dilantin; drug-induced lupus [erythematosus] |
| DILE | drug-induced lupus erythematosus |
| SCLE | Subacute Cutaneous Lupus Erythematosus |
|---|---|
| SLAM | Systemic Lupus Activity Measure |
| SLE | Systemic Lupus Erytematosus |
| SLEDAI | Systemic Lupus Erythematosus Disease Activity Index |
| SLICC/ACR | Systemic Lupus International Collaborating Clinics/American College of Rheumatology |
| lupus nephritis | Glomerulonephritis associated with systemic lupus erythematosus. It is classified into four histologic types: mesangial, focal, diffuse, and membranous. (12 Dec 1998) |
|---|---|
| lupus papillomatosus | A tuberculous skin lesion having a warty surface with a chronic inflammatory base seen on the hands in adults and lower extremities in children, with marked hypersensitivity to tuberculous antigens. See: postmortem wart. Synonym: lupus papillomatosus, lupus verrucosus, tuberculous wart, verrucous scrofuloderma. (05 Mar 2000) |
| lupus pernio | Sarcoid lesions, clinically resembling frostbite and microscopically resembling lupus vulgaris, involving ears, cheeks, nose, hands, and fingers. (05 Mar 2000) |
| lupus profundus | A subcutaneous panniculitis with marked lymphocyte infiltration of fat lobules giving rise to deep-seated, firm, rubbery nodules that sometimes become ulcerated, usually of the face; may occur in systemic and localised lupus erythematosus. Synonym: lupus profundus. (05 Mar 2000) |
| lupus sebaceus | Lupus erythematosus with lesions on the face in butterfly areas. (05 Mar 2000) |
| lupus serpiginosus | A cutaneous tuberculous lesion that spreads peripherally, healing centrally with scar formation. (05 Mar 2000) |
| lupus superficialis | Skin disease in which there are red scaly patches, especially over the nose and cheeks. May be a symptom of systemic lupus erythematosus. (18 Nov 1997) |
| lupus tuberculosus | Cutaneous tuberculosis with characteristic nodular lesions on the face, particularly about the nose and ears. Synonym: lupus tuberculosus, tuberculosis cutis luposa. (05 Mar 2000) |
| lupus verrucosus | A tuberculous skin lesion having a warty surface with a chronic inflammatory base seen on the hands in adults and lower extremities in children, with marked hypersensitivity to tuberculous antigens. See: postmortem wart. Synonym: lupus papillomatosus, lupus verrucosus, tuberculous wart, verrucous scrofuloderma. (05 Mar 2000) |
| lupus vulgaris | Cutaneous tuberculosis with characteristic nodular lesions on the face, particularly about the nose and ears. Synonym: lupus tuberculosus, tuberculosis cutis luposa. (05 Mar 2000) |
| acute parenchymatous hepatitis | A lesion in which there is extensive and rapid death of parenchymal cells of the liver, sometimes with fatty degeneration of the size of the organ; the necrosis may result from fulminant viral infection or chemical poisoning; associated with jaundice. Synonym: acute parenchymatous hepatitis, Rokitansky's disease. (05 Mar 2000) |
| anicteric hepatitis | Hepatitis without jaundice. (05 Mar 2000) |
| anicteric virus hepatitis | A relatively mild hepatitis, without jaundice, due to a virus; the principal physical signs and symptoms are enlargement of the liver, lymph nodes, and often the spleen, together with headache, continuous fatigue, nausea, anorexia, sudden distaste for smoking, abdominal pains, and sometimes mild fever; labratory tests reveal evidence of hepatitis. (05 Mar 2000) |
| autoimmune hepatitis | <pathology> A type of chronic active hepatitis that results from circulating auto-antibodies and chronic inflammation of the liver. Symptoms are those of chronic active hepatitis. (27 Sep 1997) |
| vaccination, hepatitis a | When immediate protection against hepatitis a (infectious hepatitis) is needed, immunoglobulins are used. Protection is effective only if given within 2 weeks of exposure and lasts but 2-4 months. Immunoglobulins can be used to protect household contacts of someone with acute viral hepatitis and travelers to regions with poor sanitation and high hepatitis a rates, when the traveler has to depart sooner than the vaccines can take effect (about 2 weeks). Travelers can receive the immunoglobulin and vaccine simultaneously and be protected immediately and for longer term. When immediate protection is not needed, hepatitis a vaccines are considered for individuals in high-risk settings, including frequent world travelers, sexually active individuals with multiple partners, homosexual men, individuals using illicit drugs, employees of daycare centres, and certain health care workers, and sewage workers. Two hepatitis a vaccines called havrix and vaqta are commercially available in the u.s. Both are highly effective and provide protection even after only one dose. Two doses are recommended for adults and 3 doses for children (under 18 years of age) to provide prolonged protection. (12 Dec 1998) |